Health Economics›Non-small cell lung cancer squamous›Neoadjuvant therapy

Neoadjuvant therapy

Non-small cell lung cancer squamous · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Gemcitabine (GCb) and Durvalumab N/A - protocol	—	R 268 186	28d	—	—	—	—	—
Cisplatin and Gemcitabine (GC) and Durvalumab Variant #01	—	R 266 494	28d	—	~12.9 mo	—	—	3
Carboplatin and Paclitaxel (CP) and Durvalumab Variant #01	—	R 232 277	28d	~10.2 mo	—	~12	~R 2 787 323 PFS proxy · indirect	1
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01	—	R 85 180	21d	—	—	—	—	1
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	—	—	—	2
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	~4.9 mo	~12.9 mo	~8	~R 40 246 PFS proxy · indirect	14
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	~5.3 mo	~12.9 mo	~8	~R 29 304 PFS proxy · indirect	7
Cisplatin and Gemcitabine (GC) and Nivolumab Variant #01 Partial	—	R 3 218	21d	—	—	—	—	1
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	~4.2 mo	~11.4 mo	~7	~R 3 144 PFS proxy · indirect	2

9 of 9 regimens shown